Hôpitaux Universitaires de Strasbourg, 1, avenue Molière, 67200 Strasbourg, France.
Centre Hospitalier Universitaire Amiens-Picardie, 80054 Amiens cedex 1, France.
Orthop Traumatol Surg Res. 2020 Dec;106(8):1533-1538. doi: 10.1016/j.otsr.2020.02.026. Epub 2020 Oct 28.
Prevention of venous thromboembolism (VTE) generally consists of low molecular weight heparin (LMWH) or direct oral anticoagulants (DOACs) after total hip arthroplasty (THA) or total knee arthroplasty (TKA). Enhanced recovery after surgery (ERAS) protocols may reduce the VTE risk after these procedures. The aim of this study was to compare the risk of VTE and the risk of bleeding complications in a non-selected population of primary THA and TKA cases done within an ERAS protocol.
The risk of postoperative VTE after primary THA and TKA is lower than the risk of bleeding complications within an ERAS protocol.
This was a prospective observational study conducted on a national scale in France. All patients who underwent primary unilateral THA or TKA at one of 11 participating hospitals between October 2016 and October 2017 were enrolled and followed for 3 months. The occurrence of a VTE or major bleeding event was recorded. No patients were lost to follow-up at 3 months.
Of the 1110 THA cases, there were 5 VTE (0.4%) and 19 bleeding events (1.7%). Of the 893 TKA cases, there were 9 VTE (1.0%) and 14 bleeding events (1.7%). There was no significant difference in the VTE incidence and bleeding event incidence after THA and TKA. The overall incidence of bleeding complications (1.7%) was significantly greater than the overall incidence of VTE complications (0.7%) (p=0.005). This was the case after THA (p=0.004) but not after TKA.
The primary finding of this study is that bleeding complications are significantly more common than VTE complications after THA or TKA within an ERAS protocol. Based on these findings, the cost-benefit ratio of antithrombotic prophylaxis by LMWH or DOACs in this context should be reassessed.
IV; Prospective cohort study without control group.
全髋关节置换术(THA)或全膝关节置换术(TKA)后,预防静脉血栓栓塞症(VTE)通常包括低分子肝素(LMWH)或直接口服抗凝剂(DOAC)。术后加速康复(ERAS)方案可能会降低这些手术后的 VTE 风险。本研究旨在比较 ERAS 方案内初次 THA 和 TKA 非选择性人群的 VTE 风险和出血并发症风险。
在 ERAS 方案中,初次 THA 和 TKA 术后 VTE 的风险低于出血并发症的风险。
这是一项在法国全国范围内进行的前瞻性观察性研究。2016 年 10 月至 2017 年 10 月期间,在 11 家参与医院之一接受单侧初次 THA 或 TKA 的所有患者均被纳入并随访 3 个月。记录 VTE 或大出血事件的发生情况。在 3 个月时,无患者失访。
在 1110 例 THA 病例中,有 5 例 VTE(0.4%)和 19 例出血事件(1.7%)。在 893 例 TKA 病例中,有 9 例 VTE(1.0%)和 14 例出血事件(1.7%)。THA 和 TKA 后 VTE 发生率和出血事件发生率无显著差异。出血并发症的总体发生率(1.7%)显著高于 VTE 并发症的总体发生率(0.7%)(p=0.005)。THA 后如此(p=0.004),但 TKA 后并非如此。
本研究的主要发现是,在 ERAS 方案中,THA 或 TKA 后出血并发症的发生率明显高于 VTE 并发症。基于这些发现,应重新评估 LMWH 或 DOAC 在此背景下的抗血栓预防的成本效益比。
IV;无对照组的前瞻性队列研究。